抑郁症伴糖尿病患者采用度洛西汀与氯丙咪嗪的疗效  

Efficacy of Duloxetine and Clomipramine for Depression and Diabetes

作　　者：刘进东 李丽 崔爱军 LIU Jindong;LI Li;CUI Aijun(Department of Psychiatry,Heze Third People's Hospital,Heze,Shandong Province,274000 China)

机构地区：[1]菏泽市第三人民医院精神科,山东菏泽274000

出　　处：《中外医疗》2023年第10期133-136,共4页China & Foreign Medical Treatment

摘　　要：目的分析抑郁症伴糖尿病采用度洛西汀与氯丙咪嗪治疗的效果。方法随机选取2021年1月—2022年1月期间菏泽市第三人民医院收治的抑郁症伴糖尿病患者90例作为研究对象,用随机动态数表分为对照组与观察组,各45例;所有患者入院后均接受常规降糖治疗,基于此,对照组给予氯丙咪嗪治疗,观察组给予度洛西汀治疗。比较两组患者不同阶段抑郁情况,治疗前、治疗8周后的生活质量,不良反应情况。结果治疗前,两组患者的HAMD评分比较,差异无统计学意义(P>0.05);治疗后,观察组治疗4周后、8周后HAMD评分为(20.58±3.65)分、(15.93±6.87)分明显低于对照组(24.46±4.13)分、(20.51±5.29)分,差异有统计学意义(P<0.05)。治疗前,两组患者的生活质量评分比较,差异无统计学意义(P>0.05);治疗后,两组生活质量评分比较,差异有统计学意义(P<0.05)。观察组不良反应发生率为15.56%,与对照组的35.56%比较,差异有统计学意义(χ^(2)=4.731,P<0.05)。结论相对于氯丙咪嗪而言,度洛西汀在抑郁症伴糖尿病临床治疗中有更为可观的应用价值,在促进患者康复的同时还能降低不良反应发生风险,有利于帮助患者改善生活质量。Objective To analyze the efficacy of duloxetine and clomipramine in the treatment of depression and diabetes.Methods A total of 90 patients with depression and diabetes admitted to the Third People's Hospital of Heze City from January 2021 to January 2022 were randomly selected as research objects,and were divided into control group and observation group by random dynamic number table,45 cases in each group.All patients received routine hypoglycemic treatment after admission.Based on this,clomipramine was given to the control group and duloxetine was given to the observation group.Depression at different stages,quality of life before treatment and 8 weeks after treatment,and adverse reactions were compared between the two groups.Results Before treatment,HAMD scores of the two groups were compared,and the difference was not statistically significant(P>0.05);after treatment,HAMD scores of the observation group were(20.58±3.65)points and(15.93±6.87)points after 4 weeks and 8 weeks,which were significantly lower than those of the control group(24.46±4.13)points and(20.51±5.29)points,and the difference was statistically significant(P<0.05).Before treatment,the quality of life scores of the two groups were compared,and the difference was not statistically significant(P>0.05);after treatment,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 15.56%,compared with 35.56%in the control group,and the difference was statistically significant(χ^(2)=4.731,P<0.05).Conclusion Compared with clomipramine,duloxetine has more considerable application value in the clinical treatment of depression and diabetes.It can promote the recovery of patients and also reduce the risk of adverse reactions,which is conducive to improving the quality of life of patients.

关 键 词：抑郁症 糖尿病 度洛西汀 氯丙咪嗪 HAMD评分 生活质量 

分 类 号：R587.1[医药卫生—内分泌]